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2In 2010, an estimated 6,400 Iowans will die 
from cancer, 14 times the number caused  
by auto fatalities. Cancer is becoming the 
leading cause of death in Iowa. These 
projections are based upon mortality data 
the State Health Registry of Iowa receives 
from the Iowa Department of Public 
Health. The Registry has been recording  
the occurrence of cancer in Iowa since 
1973, and is one of fourteen population-
based registries and three supplementary 
registries nationwide providing data to  
the National Cancer Institute. With 2010 
Cancer in Iowa the Registry makes a 
general report to the public on the status 
of cancer. This report will focus on:
- a description of the Registry and its goals;
- cancer estimates for 2010
- a special section on leading causes of                 
  death in the state of Iowa
- brief summaries of recent/ongoing         
  research projects
- a selected list of publications from 2009
3Cancer is a reportable disease as stated in 
the Iowa Administrative Code. Cancer data 
are collected by the State Health Registry  
of Iowa, located at The University of 
Iowa in the College of Public Health’s 
Department of Epidemiology. The staff 
includes more than 50 people. Half of 
them, situated throughout the state, 
regularly visit hospitals, clinics, and medical 
laboratories in Iowa and neighboring 
states to collect cancer data. A follow-up 
program tracks more than 99 percent of 
the cancer survivors diagnosed since 1973. 
This program provides regular updates 
for follow-up and survival. The Registry 
maintains the confidentiality of the patients, 
physicians, and hospitals providing data.
In 2010 data will be collected on an 
estimated 16,400 new cancers among Iowa 
residents. In situ cases of bladder cancer 
are included in the estimates for bladder 
cancer, to be in agreement with the 
definition of reportable cases of the 
Surveillance, Epidemiology, and End  
Results (SEER) Program of the National 
Cancer Institute. 
 Since 1973 the Iowa Registry has 
been funded by the SEER Program of the 
National Cancer Institute. Iowa represents 
rural and Midwestern populations and 
provides data included in many NCI 
publications. Beginning in 1990 about 5-10 
percent of the Registry’s annual operating 
budget has been provided by the state of 
Iowa. Beginning in 2003, the University of 
Iowa has also been providing cost-sharing 
funds. The Registry also receives funding 
through grants and contracts with 
university, state, and national researchers 
investigating cancer-related topics.
THE STATE HEALTH REGISTRY OF IOWA
THE GOALS OF THE REGISTRY ARE TO:
- assemble and report measurements of cancer incidence, 
  survival and mortality among Iowans;
- provide information on changes over time in the extent 
  of disease at diagnosis, therapy, and patient survival;
- promote and conduct studies designed to identify factors 
  relating to cancer etiology, prevention and control; 
- respond to requests from individuals and organizations 
  in the state of Iowa for cancer data and analyses; 
- provide data and expertise for cancer research activities 
  and educational opportunities. 
4LYON
70
OSCEOLA
40
DICKINSON
120
EMMET
65
KOSSUTH
110
WINNEBAGO
60
WORTH
50
MITCHELL
80
HOWARD
55
WINNESHIEK
120
ALLAMAKEE
100
CLAYTON
105
FAYETTE
140
CHICKASAW
80
BREMER
125
FLOYD
110
CERRO
GORDO
305
HANCOCK
75
PALO ALTO
75
CLAY
115
O’BRIEN
110
SIOUX
160
PLYMOUTH
145
CHEROKEE
80
BUENA VISTA
115
POCAHONTAS
60
HUMBOLDT
65
WRIGHT
100
FRANKLIN
70
BUTLER
90
DUBUQUE
500
DELAWARE
105
BUCHANAN
115
BLACK HAWK
700GRUNDY
90
HARDIN
120
HAMILTON
95
WEBSTER
235
CALHOUN
75
SAC
80
IDA
55
WOODBURY
515
MONONA
70
CRAWFORD
100
CARROLL GREENE
65
BOONE
145
STORY
320
MARSHALL
240
TAMA
115
BENTON
140
LINN
1015
JONES
110
JACKSON
125
CLINTON
310CEDAR
105JOHNSON
430
IOWA
115
POWESHIEK
105
JASPER
220
POLK
1860
DALLAS
230
GUTHRIE
80
AUDUBON
50
SHELBY
80
HARRISON
115
POTTAWATTAMIE
500
CASS
80
ADAIR
55
MADISON
85
WARREN
215
MARION
175
MAHASKA
125
KEOKUK
65
WASHINGTON
125
MUSCATINE
220
LOUISA
65
DES MOINES
265
HENRY
105
JEFFERSON
85
WAPELLO
215
MONROE
55
LUCAS
55
CLARKE
50
UNION
75
ADAMS
30
MONTGOMERY
75
MILLS
80
FREMONT
55
PAGE
125
TAYLOR
40
RINGGOLD
35
DECATUR
50
WAYNE
50
APPANOOSE
90
DAVIS
50
VAN BUREN
50 LEE
240
SCOTT
870
120
LYON
25
OSCEOLA
15
DICKINSON
50
EMMET
25
KOSSUTH
45
WINNEBAGO
25
WORTH
20
MITCHELL
25
HOWARD
20
WINNESHIEK
40
ALLAMAKEE
35
CLAYTON
45
FAYETTE
55
CHICKASAW
25
BREMER
50
FLOYD
40
CERRO
GORDO
110
HANCOCK
20
PALO ALTO
30
CLAY
45
O’BRIEN
40
SIOUX
50
PLYMOUTH
60
CHEROKEE
35
BUENA VISTA
45
POCAHONTAS
25
HUMBOLDT
25
WRIGHT
40
FRANKLIN
25
BUTLER
40
DUBUQUE
210
DELAWARE
35
BUCHANAN
50
BLACK HAWK
265GRUNDY
30
HARDIN
55
HAMILTON
35
WEBSTER
100
CALHOUN
30
SAC
35
IDA
20
WOODBURY
215
MONONA
30
CRAWFORD
40
CARROLL GREENE
25
BOONE
60
STORY
120
MARSHALL
100
TAMA
50
BENTON
50
LINN
365
JONES
40
JACKSON
45
CLINTON
115CEDAR
40JOHNSON
145
IOWA
40
POWESHIEK
45
JASPER
95
POLK
720
DALLAS
85
GUTHRIE
30
AUDUBON
15
SHELBY
35
HARRISON
45
POTTAWATTAMIE
215
CASS
40
ADAIR
25
MADISON
35
WARREN
85
MARION
75
MAHASKA
50
KEOKUK
20
WASHINGTON
50
MUSCATINE
90
LOUISA
30
DES MOINES
105
HENRY
45
JEFFERSON
35
WAPELLO
95
MONROE
20
LUCAS
25
CLARKE
20
UNION
35
ADAMS
10
MONTGOMERY
30
MILLS
25
FREMONT
15
PAGE
50
TAYLOR
20
RINGGOLD
15
DECATUR
20
WAYNE
20
APPANOOSE
45
DAVIS
15
VAN BUREN
25 LEE
95
SCOTT
320
55
ESTIMATED NUMBER OF NEW CANCERS IN IOWA FOR 2010
ESTIMATED NUMBER OF CANCER DEATHS IN IOWA FOR 2010
CANCER PREDICTIONS FOR 2010
5CANCER DEATHS IN MALES
Type                    # of Cancers    % of Total
Lung 1020 30.9
Prostate 350 10.6
Colon & Rectum 290 8.8
Pancreas 180 5.5
Leukemia 150 4.6
Bladder 150 4.6
Esophagus 140 4.2
Non-Hodgkin Lymphoma 130 3.9
Kidney & Renal Pelvis 120 3.6
Brain 100 3.0
All Others 670 20.3
Total 3300
CANCER DEATHS IN FEMALES
Type                     # of Cancers   % of Total
Lung 780 25.1
Breast 440 14.2
Colon & Rectum 320 10.3
Pancreas 190 6.1
Ovary 180 5.8
Non-Hodgkin Lymphoma 120 3.9
Leukemia 120 3.9
Uterus 100 3.2
Brain 70 2.3
Kidney & Renal Pelvis 70     2.3
All Others 710 22.9
Total 3100
NEW CANCERS IN MALES
Type        # of Cancers   % of Total
Prostate   2200 26.2
Lung    1300 15.5
Colon & Rectum  830 9.9
Bladder    620 7.4
(invasive and noninvasive) 
Non-Hodgkin Lymphoma 400 4.8
Skin Melanoma  350 4.1
Kidney & Renal Pelvis 350 4.1
Leukemia   250 3.0
Oral Cavity   220 2.6
Pancreas   190 2.3
All Others   1690 20.1
Total             8400
NEW CANCERS IN FEMALES
Type                     # of Cancers   % of Total
Breast 2200 27.5
Lung 1000 12.5
Colon & Rectum 900 11.2
Uterus 500 6.2
Non-Hodgkin Lymphoma 350 4.4
Skin Melanoma 300 3.8
Ovary 250 3.1
Kidney & Renal Pelvis 230 2.9
Thyroid 220 2.8
Leukemia 210 2.6
All Others 1840 23.0
Total 8000
TOP TEN TYPES OF CANCER IN
IOWA ESTIMATED FOR 2010
6 Cause of death has been examined for 
many years as a means of monitoring public 
health. Mortality rates can be created for heart 
disease by expressing the number of heart 
disease deaths per 100,000 population. 
The same can be done for cancer deaths. 
There are three common ways these rates are 
presented: 1) age-specific rates, 2) crude rates, 
and 3) age-adjusted rates.  Age-specific rates 
are calculated by taking the total number of 
deaths of a specific cause divided by the total 
population count at the time of the deaths 
across a specified age group, for example, 
80 to 84 years of age.  A crude rate is the 
weighted average of the individual age-specific 
rates, with the weights being the proportion of 
the actual population in each category. 
An age-adjusted rate is 
also a weighted average of 
the individual age-specific 
rates, but here the weights 
used are the proportion of 
a standard population in each category. The 
standard being used today in the U.S. is the 
2000 U.S. population. Researchers prefer using 
age-adjusted rates because they can compare 
these rates with the assurance that the 
underlying age-specific population weights are 
exactly the same, and consequently, differences 
in these rates will be due to differences in the 
age-specific rates. 
 When using age-adjusted rates, it is 
important to remember that they should 
only be compared when the same standard 
population is being applied. For this reason, 
U.S. government agencies are currently 
required to use the 2000 U.S. population 
as their standard. 
Figure 1.  Heart Disease Deaths versus Cancer Deaths, Iowa, 1973-2007
(Rates are age-adjusted to 2000 U.S. population and expressed per 100,000 population)    
 
Heart Disease
Cancer The cancer age-adjusted  
rate exceeded the heart 
disease rate for the  
first time in 2007.
CANCER BECOMES NUMBER ONE
CAUSE OF AGE-ADJUSTED 
DEATH 
7other programs, and improved treatments for 
the disease. Risk factors usually affect disease 
development over the long term rather than 
the short term, so education and prevention 
efforts begun decades ago are reflected in the 
current decreased rates for both diseases. 
 Given the increasing rates of obesity in 
the state of Iowa, diabetes has been increasingly 
diagnosed. Since diabetes and obesity are risk 
factors for heart disease, it is possible that the 
number one cause of age-adjusted death could 
fluctuate in Iowa over the next few years.  
 For decades, cancer and heart disease 
have combined to account for nearly 50% or 
more of all causes of death in Iowa. In 1994 
they accounted for 57% of all deaths; in 2007, 
49% of all deaths. The declining percent is a 
reflection of the trend of decreasing annual 
rates that each of these leading causes of death 
has been experiencing (Figure 1).   
 When evaluating age-specific mortality 
rates in 2007 for both sexes combined, both 
cancer and heart disease were relatively rare 
under 55 years of age (Figure 2). Between  
Figure 2.  Average Annual Age-Specific Mortality Rates in Iowa, 
Cancer vs. Heart Disease, 2007  
 (Rates expressed per 100,000 population) 
Cancer         Heart Disease
The cancer age-adjusted  
rate exceeded the heart 
disease rate for the  
first time in 2007.
Annual age-adjusted death rates, using 
the 2000 U.S.  population as the standard,  
are presented for cancer and heart disease for 
a 35-year period in Figure 1. One important 
observation in looking at this figure is that 
in 2007, cancer replaced heart disease as the 
number one cause of death in Iowa for the  
very first time. Prior to this heart disease  
has always been the number one cause of  
age-adjusted death and in the 1970s these  
heart disease rates were over twice as high 
as the cancer rates.    
 Since 1994 in Iowa, age-adjusted death 
rates have been declining for both cancer and 
heart disease (Figure 1). Between 1994 and 
2007, these rates declined 13% for cancer and 
35% for heart disease. The decline for heart 
disease has been greater, which explains why 
cancer became the number one cause of age-
adjusted death in 2007. Reasons for the declines 
in both diseases include decreasing frequency of 
risk factors, such as the rate of smoking, earlier 
detection of people with these diseases, when 
they are more treatable, through screening and 
855 and 79 years of age, cancer was the leading 
cause of death in both sexes. In the two oldest 
age groups, heart disease remained the number 
one cause. 
 When these age-adjusted rates are 
stratified by sex, female cancer death rates have 
exceeded female heart disease death rates since 
2004 (data not shown). In 2007, female cancer 
death rates exceeded heart disease death rates 
by 17 per 100,000 population (151/100,000 vs. 
134/100,000). On the other hand, as of 2007, 
male cancer death rates have not yet exceeded 
heart disease death rates (216/100,000 vs. 
224/100,000), but the gap is narrowing (Table 1). 
 In 2007, age-adjusted mortality rates for 
cancer exceeded those for heart disease among 
whites, blacks, and other racial groups (Table 
1). After dividing Iowa’s 99 counties into four 
groups based on population, as was done in the 
2009 Iowa Health Fact Book (see http://www.
public-health.uiowa.edu/factbook/, Introduction, 
page 3), age-adjusted cancer mortality rates 
exceeded heart disease rates only in counties 
classified as part of metropolitan statistical 
areas (MSA). These counties are defined by 
the U.S. Census Bureau as having a central 
city along with counties economically and 
socially connected to it. An MSA must have a 
central city with at least 50,000 inhabitants or 
a census-defined urbanized area with a total 
metropolitan population of at least 100,000.
 In Table 2, both crude and age-adjusted 
mortality rates have been calculated for the 
U.S., Iowa, and its surrounding states for the 
year 2006, the most recent year for which 
these data are readily available. Minnesota was 
the only adjacent state where cancer mortality 
rates exceeded heart disease mortality rates 
for both crude and adjusted rates; this first 
occurred in the year 2000. In Nebraska and 
Wisconsin, the 2006 adjusted cancer mortality 
rates were exceeding their corresponding 
Table 1.  Cancer vs. Heart Disease Mortality Rates in Iowa, 2007
               CanCeR            HeaRT DIsease
 number Rate* number Rate*
Iowa  6,358 177 6,843 173
Gender    
Male 3,265 216 3,374 224
Female 3,093 151 3,469 134
Race**    
 White 6,216 177 6,734 173
 Black 102 252 84 196
 Other 37 114 22 92
County Groups    
< 10,000 population 445 170 608 190
 10,000 - 20,000 population 1,328 169 1,631 177
 > 20,000 population 1,468 179 1,691 187
 Metropolitan statistical area 3,117 182 2,913 161
* Age-adjusted to 2000 U.S. population and expressed per 100,000 population
** Numbers do not sum to total because of unknown race
9heart disease rates for the first time, but the 
crude rates have yet to do this. In all the other 
surrounding states as well as Iowa and the 
entire United States, in 2006 neither the 
age-adjusted nor crude cancer mortality rates 
have yet exceeded the heart disease mortality 
rates. Nevertheless, the trend in all these areas 
shows the gap to be narrowing between these 
rates similar to what is shown in Figure 1. The 
primary reason the crude rates have not yet 
exceeded the age-adjusted rates is that the 2006 
populations in these states have a greater per- 
centage of their respective populations over the 
age of 79 than the 2000 U.S. standard population. 
For example in 2006, 4.9% of Iowa’s population 
and only 3.3% of the 2000 U.S. standard 
population was 80 years of age and older. 
The 13% decrease in age-adjusted 
cancer mortality rates between 1994 and 2007 
(203.2 per 100,000 and 177.1 per 100,000, 
respectively) has primarily been the result of 
decreases in prostate, female breast, colorectal, 
and lung cancers. During this same time period, 
the rate declines for these sites have been 37%, 
34%, 29%, and 5%, respectively.         
 The decline in prostate cancer mortality 
is primarily attributed to better treatment 
and increasing application of effective treatment. 
In 2009 two separate clinical trials evaluating 
prostate specific antigen (PSA) did not show 
this test to be effective in reducing prostate 
cancer mortality for the 10-year period 
following diagnosis. For female breast cancer, 
research results support mammography 
screening and improved treatments as having 
equally contributed to fewer women dying 
from breast cancer. Declines in colorectal 
cancer death rates are consistent with a 
relatively large contribution from screening 
and with a smaller but demonstrable impact 
from risk factor reduction and improved 
treatments. The declines in lung cancer deaths 
can be attributed to declines in tobacco use, 
particularly cigarette use among males. 
Table 2.  Cancer vs. Heart Disease Mortality Rates 
 for the U.s. and selected states, 2006
   CanCeR                        HeaRT DIsease
 number        adjusted       Crude     number      adjusted    Crude
   Rate*          Rate**       Rate*       Rate**
United States 559,880 181 187 631,596 200 211
South Dakota 1,570 170 199 1,757 174 223
Minnesota 9,079 172 176 7,525 133 146
Nebraska 3,430 177 194 3,445 164 195
Iowa  6,359 180 214 7,172 183 241
Wisconsin 10,925 181 196 11,451 179 205
Illinois  24,083 188 188 27,006 204 211
Missouri 12,519 196 214 14,749 223 253
* Age-adjusted to 2000 U.S. population and expressed per 100,000 population
** Per 100,000 population
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The State Health Registry of Iowa is 
participating in around seven dozen funded 
studies during 2010. Brief descriptions of  
a few of these studies are provided.
AGRICULTURAL HEALTH STUDY
The Agricultural Health Study is a long-term 
study of agricultural exposures (including 
pesticides) and chronic disease (especially 
cancer) among commercial or private pesticide 
applicators (and their spouses, if married) 
in Iowa and North Carolina. The study is 
funded primarily by the National Cancer 
Institute. We are in the 18th year of the study, 
which received renewed funding at the end  
of 2003 for continuation into 2010. 
 In the first five years, 89,658 subjects 
(58,564 in Iowa and 31,094 in North Carolina) 
were enrolled in the study. This total for Iowa 
included 31,877 private applicators, 21,771 
spouses of private applicators, and 4,916 
commercial applicators. Enrollment consisted  
of completing questionnaires about past 
exposures and health. The second phase  
of the study for private applicators and their 
spouses was completed at the end of 2003. 
It involved a telephone interview, a mailed 
dietary questionnaire, and collection of  
a cheek cell sample from all consenting cohort 
members. The telephone interview asked about 
pesticide use since enrollment, current farming 
and work practices, and health changes.  
The dietary health questionnaire asked about 
cooking practices and types of foods eaten. 
Cooking practices and diet may play a role in 
cancer and other health conditions. The cheek 
cells are being used to understand possible  
links between genetics, exposures, and disease. 
For commercial applicators, the second phase 
of the study was completed at the end of 2005. 
The study’s third phase began in 2005, involves 
updating information about exposures and 
health, and will be completed this year. Plans for 
a fourth phase of the study are being developed. 
 Since 1997, cohort members have been 
linked annually to mortality and cancer registry 
incidence databases in both states. In addition, 
mortality data on the cohort are being obtained 
from the National Death Index. More 
information about recent results from this 
study, the study background, frequently asked 
questions, other resources (internet & 
telephone) for agricultural health information, 
references for publications to date, and 
information for scientific collaborators can  
be found at the website, www.aghealth.org. 
The abstracts for the publications are available  
at this website. The cancer-related references 
for 2009 publications are provided in the last 
section of this report. 
    
IOWA WOMEN’S HEALTH STUDY
This is a population-based cohort of 41,837 
Iowa women, aged 55-69 in 1986, who were 
recruited to determine whether diet, body fat 
distribution and other risk factors were related 
to cancer incidence. Exposure and lifestyle 
information was collected in a baseline mailed 
survey and subsequently in several follow-up 
mailed surveys. Mortality and cancer incidence 
have been ascertained since 1986 through 
annual linkage to the State Health Registry of 
Iowa databases and the National Death Index.  
The project has been extremely productive with 
over 200 publications, some of which occurred  
in 2009 and are listed in the references provided 
in the last section of this report. 
NON-HODGKIN LYMPHOMA (NHL)  
CASE-CONTROL STUDY
The State Health Registry of Iowa (SHRI) 
with researchers at the Mayo Clinic participated 
in a collaborative, population-based case-
control study of NHL involving researchers at 
the National Cancer Institute and three other 
Surveillance, Epidemiology, and End Results 
(SEER) registries. The main objective of the 
study was to better characterize risk factors for 
NHL. In Iowa, 364 live patients newly diagnosed 
with NHL between July 1, 1998 and June 30, 
RESEARCH PROJECTS DURING 2010
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2000 were enrolled. A similar number of 
population controls participated. Blood samples 
were sought from study participants. The SHRI 
also coordinated the acquisition of pathology 
reports, slides and tissue blocks from all SEER 
centers. The slides were reviewed to determine 
the reliability of NHL pathologic classification. 
More recently, we are collaborating with 
researchers at the Mayo Clinic to investigate 
whether genes with functional, common variant 
polymorphisms involved in immune function and 
regulation are associated with overall survival 
from NHL among these patients. To achieve this 
aim, medical record reviews were performed  
to obtain more detailed information on the 
treatment received for NHL. These research 
activities resulted in several publications during 
2009. The references for these are provided in 
the last section of this report. 
PATTERNS OF CARE STUDIES
SEER Patterns of Care Studies are conducted 
to satisfy a U.S. Congressional directive to  
the National Cancer Institute to “assess  
the incorporation of state-of-the-art cancer 
treatment into clinical practice and the  
extent to which cancer patients receive such 
treatments.” This year’s Patterns of Care Study 
will involve prostate cancer, non-Hodgkin 
lymphoma, chronic lymphocytic leukemia, and 
gastrointestinal stromal tumors (sarcoma) in 
adults diagnosed between January 1, 2008 and 
December 31, 2008. The objectives of the SEER 
Patterns of Care Study are to:1) describe the 
use of adjuvant therapy, which has been verified 
with the treating physician, in a community 
setting, 2) characterize the practice patterns  
in different communities, 3) describe more 
completely the use of surgery in the treatment 
of specific cancers, 4) compare the patterns 
of treatment for cancer over time, 5) compare 
patterns of care by age and race/ethnicity,  
6) describe the effect of co-morbid conditions 
on treatment, and 7) describe treatment 
by hospital characteristics: i.e. for profit vs. 
not for profit, teaching vs. non-teaching, 
disproportionate share status, etc. The SHRI 
has been involved with these types of studies 
over the past 20 years. During 2009, they have 
resulted in a couple of publications, which are 
provided in the last section of this report. 
POOLED ANALYSES
Today, researchers are increasingly looking 
to combine their study data with that of 
other studies evaluating similar exposures 
and outcomes. During 2009 these activities 
resulted in a couple of publications, which are 
listed in the last section of this report, involving 
pancreatic cancer and non-Hodgkin lymphoma.   
   
SECOND CANCER STUDIES
 
Over the past two decades, the State Health 
Registry of Iowa has participated in several 
second cancer studies. These have consisted 
of cohorts with a first cancer of the cervix, 
ovary, testis, uterus, female breast, non-Hodgkin 
lymphoma, or Hodgkin disease. They have been 
conducted primarily in collaboration with the 
Radiation Epidemiology Branch at the National 
Cancer Institute and other registries in North 
America and Europe. Generally these studies 
evaluate the treatment received for the first 
cancer and the risk it places on the patient for 
development of a second cancer. They typically 
involve medical record review and pathology 
material retrieval.  
 The WECARE (Women’s Environmental 
Cancer and Radiation Epidemiology) Study 
is another example of a second cancer study. 
This study is designed to examine gene carrier 
status, demographic and lifestyle factors as 
well as environmental and treatment factors 
reported to be associated with breast cancer 
as they relate to the development of a second 
breast cancer in the opposite breast. Data 
collection not only involved medical record 
review, but also participant interviews and 
blood sample collection. This year, we are going 
back into the field to add more participants to 
this study to enable a genome-wide association 
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study to be conducted to learn more about 
how genetic, environmental, and lifestyle factors 
work together to influence whether a woman 
with breast cancer will develop a second breast 
cancer in the opposite breast.     
 Results from the second cancer studies 
have provided important medical information 
and will continue to do so in the future. 
A few publications during 2009 involving 
second cancers are provided in the last 
section of this report.
SEER-MEDICARE
In the early 1990s, the cancer incidence and 
survival data from the State Health Registry 
of Iowa were combined with other SEER 
Registry data and linked to Medicare data. 
This linked data set has been updated on 
several occasions since and has become an 
important data resource for cancer research 
regarding epidemiologic and health services 
research related to the diagnosis, treatment 
and procedures, costs, and survival of cancer 
patients. Over the years many publications 
have resulted from this linked data set including 
several during 2009, a selected subset of which 
are provided in the last section of this report. 
STUDIES OF CANCER SURVIVORS
 
A few years ago, two studies were funded by 
the American Cancer Society (ACS) with the 
specific aims to: 1) describe the unmet needs 
of cancer survivors, with a particular focus on 
their psychosocial adjustment and quality of life; 
2) identify factors that determine good quality 
of life and successful survivorship; 3) provide  
a database to use in assessing the relevance  
and effectiveness of ACS programs intended  
to meet the needs of cancer survivors;  
and 4) examine factors that relate to the 
development and possible prevention of late 
effects, including second cancers. Several 
hundred Iowa patients were enrolled in  
these studies and they have been responding  
to mailed questionnaires received around  
1, 2, 5, and 10 years after diagnosis. These data 
are now being analyzed and have resulted in  
a couple of 2009 publications that are listed in 
the last section of this report. 
 The Adolescent and Young Adult Health 
Outcomes and Patient Experience (AYA HOPE) 
Study is another ongoing example of a cancer 
survivor study. This study is an initial step in 
addressing potential factors related to gaps in 
research, care and outcomes for AYA cancer 
patients.  At seven SEER Registries across the 
United States, 530 patients (40 in Iowa), 15-39 
years old at diagnosis between July 1, 2007 and 
October 31, 2008 have been enrolled with any 
of the following cancers: ovarian or testicular 
cancer, Hodgkin lymphoma, non-Hodgkin 
lymphoma, acute lymphoblastic leukemia,  
or selected types of sarcoma. This year these 
patients are being recontacted to obtain 
additional follow-up information regarding 
their cancer survivorship experience.  
Reports will be forthcoming regarding factors 
related to access to care, treatment and  
follow-up care, and impact of cancer on  
physical and psychosocial functioning. 
COOPERATIVE AGREEMENTS AND  
OTHER REGISTRIES
The SHRI maintains cooperative agreements 
with several hospital cancer registries and other 
agencies/entities. Some of the latter include:
- Iowa Department of Public Health
- Iowa Cancer Consortium 
- The University of Iowa
 - Center for Health Effects of 
   Environmental Contamination
 - Center for Public Health Statistics
    - Environmental Health Sciences 
  Research Center
 - Health Effectiveness Research Center
   - Holden Comprehensive Cancer Center
    - Iowa Center for Agricultural Safety 
       and Health
 - Iowa Registry for Congenital and    
    Inherited Disorders
    - Injury Prevention Research Center
    - Preventive Intervention Center 
   - Reproductive Molecular Epidemiology   
  Research & Education Program
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